Cambridge Innovation Capital brings in £225M for 2nd fund

Cambridge Innovation Capital Ltd. received £225 million for its second fund, attracting capital from some 50 institutional and strategic investors.

Fund II has made six investments thus far, including quantum computing software provider Riverlane, mitochondrial therapeutics developer Pretzel Therapeutics Inc., photonic computing company Salience Labs Ltd. and cancer immunotherapeutics manufacturer Epitopea.

The venture capital firm was formed to increase the success rate of businesses incubated at the University of Cambridge and in the larger Cambridge ecosystem.